Braintree Company Profile
What is the competitive landscape for BRAINTREE
BRAINTREE has four approved drugs.
There is one US patent protecting BRAINTREE drugs.
Summary for Braintree
| US Patents: | 1 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Braintree
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braintree Labs | PIZENSY | lactitol | FOR SOLUTION;ORAL | 211281-001 | Feb 12, 2020 | DISCN | Yes | No | 10,806,743 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Braintree | AXID | nizatidine | SOLUTION;ORAL | 021494-001 | May 25, 2004 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Braintree Labs | SUCLEAR | magnesium sulfate; polyethylene glycol 3350; potassium chloride; potassium sulfate; sodium bicarbonate; sodium chloride; sodium sulfate | SOLUTION;ORAL | 203595-001 | Jan 18, 2013 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Braintree | HALFLYTELY | bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL | 021551-003 | Jul 16, 2010 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Braintree
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Braintree | HALFLYTELY | bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL | 021551-003 | Jul 16, 2010 | 7,291,324 | ⤷ Start Trial |
| Braintree | AXID | nizatidine | SOLUTION;ORAL | 021494-001 | May 25, 2004 | 6,930,119 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRAINTREE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Oral Solution and Delayed-release Tablet | 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen) | ➤ Subscribe | 2010-07-30 |
| ➤ Subscribe | For Oral Solution and Delayed- | 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg | ➤ Subscribe | 2008-01-28 |
| ➤ Subscribe | Oral Solution | 15 mg/mL | ➤ Subscribe | 2008-05-14 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
